Keimyung University Dongsan Medical Center
dsmc.or.krTotal trials
80
Active
3
Phase 3
6
Total enrollment
1,386,466
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Busulfan | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | — | 1 |
Next readouts
- 2025-12
Top conditions
- Pain, Chronic9
- Atrial Fibrillation6
- Optic Nerve Sheath Diameter5
- Coronary Artery Disease4
- Gastric Cancer3
- Intravascular Injection2
- Thoracic Epidural Injection2
- General Anesthesia2
Frequently asked questions about Keimyung University Dongsan Medical Center
- How many clinical trials does Keimyung University Dongsan Medical Center have on ClinicalTrials.gov?
- Keimyung University Dongsan Medical Center is listed as the lead sponsor on 80 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Keimyung University Dongsan Medical Center's trials are in Phase 3?
- 6 of Keimyung University Dongsan Medical Center's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Keimyung University Dongsan Medical Center focus on?
- Keimyung University Dongsan Medical Center's most-studied conditions on ClinicalTrials.gov are Pain, Chronic, Atrial Fibrillation, Optic Nerve Sheath Diameter, Coronary Artery Disease, Gastric Cancer.
- When are Keimyung University Dongsan Medical Center's next clinical trial readouts?
- Keimyung University Dongsan Medical Center has 1 upcoming primary-completion readout tracked here; the soonest is “Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas”, expected around 2025-12.